Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03509051

Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation — MENINGREF  

Hematopoietic Stem Cell Transplant Clinical Trial

Official title:
Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation

Clinical Trial Summary

Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at risk of various bacterial infections, especially due to a progressive decrease of specific antibodies. Around 90% of HSCT recipients have unprotective titers of specific antibodies to serogroups A and C meningogocci (Parkkali 2001; Mahler 2012). Some small studies suggest that the response to meningococcal A and C vaccines is close to 100% after 3 doses given 18 months after transplant. Although the response to 2 doses of 4CMenB is over 75% in other immunocompromised patients (Feavers, 2017), studies with 4CMenB are lacking after HSCT. Nevertheless, as serogroup B caused 74% of IMD in Europe between 2004-2014 (Whittaker, 2017), the meningococcal B vaccination is recommended by the more recent guidelines from 6 months after transplant. There are, however, no data on the safety and efficacy of this vaccine after hematopoietic stem cell allograft (HSCT). The objective of this study is to assess the response to 2 doses of a multicomponent meningococcal B vaccine (4CMenB) given at 2 months interval in adult allogeneic HSCT recipients transplanted at least 6 months ago. The response will be assessed 1 month and 10 months after the second dose of vaccine by measuring bactericidal antibodies against NadA, fHbp, NHBA and PorAP1 vaccinal antigens according to methods previously reported (Caron Lancet Infect Dis 2011). The response rate will be correlated to pre- and post-transplant factors. The hypothesis of this study is that 80% of the patients should have protective titers one month after the 2nd dose.

Clinical Trial Description

Monocentric study. Forty patients are expected. Primary objective: Response rate one month after 2 doses of vaccine Secondary objectives: safety, rate of protection before vaccination, comparison of the antibody titers at one month vs. at 10 months after the vaccine program. Relationship between pre and post-transplant factors. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03509051
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase N/A
Start date June 1, 2019
Completion date March 13, 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT02451462 - Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients N/A
Terminated NCT01215981 - Influenza Vaccine Post Allogeneic Transplant N/A
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Completed NCT01337648 - Radiation Biodosimetry in Children Undergoing Total Body Irradiation N/A
Recruiting NCT03250546 - Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem Cell Transplant Phase 2
Not yet recruiting NCT05722210 - Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Recruiting NCT02982902 - T Cell Therapy of Opportunistic Cytomegalovirus Infection Early Phase 1
Completed NCT02441075 - 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014 N/A
Completed NCT04549038 - Time Restricted Nutrition in Pediatric Stem Cell Transplant Recipients N/A
Completed NCT03886909 - Impact of Prehabilitation in Oncology Via Exercise- Bone Marrow Transplant N/A
Not yet recruiting NCT06328127 - Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors N/A
Terminated NCT02350777 - T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT04853277 - Patient Reported Outcomes and Patient Education in Cellular Therapy Patients N/A
Completed NCT03378089 - Music Therapy and Hematopoietic Stem Cell Transplant N/A
Completed NCT03039257 - Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates N/A
Completed NCT03202849 - A Randomized Trial of Vitamin D Supplementation With or Without Vitamin A in Stem Cell Transplantation N/A
Completed NCT01581164 - Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation N/A
Completed NCT01504152 - International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center N/A
Completed NCT03759262 - Ultra-high Dose Vitamin D for HSCT N/A
Recruiting NCT04263597 - Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients Phase 1/Phase 2